Almudena Moreno-Borrallo

Ms. Almudena Moreno-Borrallo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Acta Biomaterialia
Verified
Journal Article
Open access
CJCarla Jiménez-Jiménez
Carla Jiménez-Jiménez
AMAlmudena Moreno-Borrallo
Almudena Moreno-Borrallo
BDBianca Dumontel
Bianca Dumontel
MMMiguel Manzano
Miguel Manzano
MVMaría Vallet-Regí
María Vallet-Regí

Verified
Journal Article
Open access
PDF file
PTPeter Takac
Peter Takac
RMRadka Michalková
Radka Michalková
MČMARTINA ČIŽMÁRIKOVÁ
MARTINA ČIŽMÁRIKOVÁ
Zdenka BedlovičováZdenka Bedlovičová
Zdenka Bedlovičová
ĽBĽudmila Balážová
Ľudmila Balážová
PTPeter Takáč
Peter Takáč
Silver nanoparticles (AgNPs) have emerged as promising agents in cancer diagnostics and/or therapy, demonstrating a lot of possible pharmacological actions. However, understanding the pharmacokinetics and safety profiles of nanoparticles, which is crucial for their clinical application, still raises many questions. Studies indicate that AgNPs can accumulate in tumour tissues, improving drug delivery and specificity. However, their interaction with biological systems necessitates thorough safety evaluations. Classical methods for assessing AgNPs’ safety include cytotoxicity assays, genotoxicity tests, and histopathological examinations. However, novel techniques are emerging, such as advanced imaging and biomarker analysis, offering more precise toxicity assessments. Prediction models, including computational simulations and in silico analyses, are being developed to forecast AgNPs’ toxicity profiles. These models aim to reduce reliance on animal testing and expedite the evaluation process. To mitigate potential risks associated with nanoparticle-based therapies, strategies such as surface modification, controlled release systems, and targeted delivery are being explored. These methods aim to enhance therapeutic efficacy while minimizing adverse effects. The main aim of this review article is to describe AgNPs from the point of view of their pharmacokinetic/toxicokinetic profile in the light of modern knowledge. Special attention will be given to novel methods for assessing the safety and toxicity profiles of AgNPs, providing insights into their interactions with cancer therapies and their potential clinical applications.

5 August 2026 in RSC Sustainability
Verified
Journal Article
Open access
AMAlmudena Moreno-Borrallo
Almudena Moreno-Borrallo
MFMary E. Flood
Mary E. Flood
WBWiktoria Brytan
Wiktoria Brytan
JBJoseph P. Byrne
Joseph P. Byrne
FAFRANCESCA ADAMI
FRANCESCA ADAMI
This Forum article evaluates the impact and gathers insights from the 2024 Young Chemists for Change (YCFC) conference, an equality, diversity and inclusion (EDI)-centred event for early-career chemists in Ireland and the UK.

7 August 2026 in Materials Today Advances
Verified
Journal Article
Open access
AMAlmudena Moreno-Borrallo
Almudena Moreno-Borrallo
RMRebecca Maher
Rebecca Maher
EGElisabet Gómez-González
Elisabet Gómez-González
TAThomson Santosh Alex
Thomson Santosh Alex
OKOisin Kearns
Oisin Kearns
EREduardo Ruiz-Hernández
Eduardo Ruiz-Hernández